Molecular Biosystems to commence Phase 2 trials for ORALEX.SAN DIEGO--(BUSINESS WIRE)--Oct. 24, 1995--Molecular Biosystems Inc. (NYSE NYSE See: New York Stock Exchange :MB) Tuesday announced the commencement of Phase 2 human clinical trials for ORALEX, the company's orally administered gastrointestinal agent for enhancing abdominal imaging. The objective of the Phase 2 trials will be to assess the efficacy of ORALEX to improve the visualization of the stomach and pancreas using ultrasound. The ability to distinguish between normal and diseased tissue is an important component of the diagnostic process used by internal medicine, surgery and gastroenterology gastroenterology Medical specialty dealing with digestion and the digestive system. In the 17th century Jan Baptista van Helmont conducted the first scientific studies in the field; William Beaumont published his own observations in 1833. specialists for evaluating gastrointestinal disorders. ORALEX-enhanced ultrasound may provide imaging capabilities not available with alternative procedures. The results from the recently completed ORALEX Phase 1 trials successfully enhanced abdominal images and demonstrated no significant safety problems. ORALEX was shown to be more effective than the control, water, which is the only agent currently used to improve abdominal imaging. ORALEX facilitated the displacement of gas in the stomach and provided an acoustic window which enhanced the ability to visualize the pancreas and stomach wall. It was also effective in slowing the gastric emptying process. "ORALEX may offer significant advantages over more invasive and costly procedures, such as endoscopy endoscopy Examination of the body's interior through an instrument inserted into a natural opening or an incision, usually as an outpatient procedure. Endoscopes include the upper gastrointestinal endoscope (for the esophagus, stomach, and duodenum), the colonoscope (for the and computed tomography Computed tomography (CT scan) X rays are aimed at slices of the body (by rotating equipment) and results are assembled with a computer to give a three-dimensional picture of a structure. , by providing a safe and economical alternative imaging technique for patients with known or suspected pancreatic and stomach disease," stated Kenneth J. Widder, M.D., MBI's chairman and chief executive officer. Molecular Biosystems Inc. based in San Diego, is a leader in the development of ultrasound contrast agents for medical imaging. In August 1994, MBI MBI Management Buy-In MBI Moody Bible Institute MBI Mathematical Biosciences Institute MBI Modular Building Institute MBI Mechanical Breakdown Insurance MBI Molecular Biology Institute MBI Maslach Burnout Inventory (psychometrics) received final approval from the U.S. Food and Drug Administration to begin domestic marketing of ALBUNEX, MBI's flagship ultrasound contrast agent. ALBUNEX is currently marketed in Japan by Shionogi & Co. Ltd., and in the United States by Mallinckrodt Medical Inc. (Mallinckrodt Group Inc., NYSE:MKG MkG Mit Kameradschaftlichen Grüßen (German: With Best Regards) MKG Mitsubishi Kreditbank GMBH (German branch of Mitsubishi Bank) MKG Muskegon, MI, USA - Muskegon County International Airport ). Hafslund Nycomed AS (NYSE:HN) will market ALBUNEX in Europe. MBI shares are listed on the New York Stock Exchange New York Stock Exchange (NYSE) World's largest marketplace for securities. The exchange began as an informal meeting of 24 men in 1792 on what is now Wall Street in New York City. under the symbol "MB." CONTACT: Molecular Biosystems Inc., San Diego Gerard A. Wills/Stephen F. Keane, 619/452-0681, ext. 2212 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion